Document Classification

Section Type: RESULTS

Text: At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50. 7 %, 57. 1 %, and 54. 2 %, respectively, versus 10. 0 % for placebo (p < / = 0. 001 for all comparisons) ; ACR50 rates were 23. 9 %, 27. 1 %, and 19. 4 %, respectively, versus 1. 4 % for placebo (p < / = 0. 001 for all comparisons) ; and ACR70 rates were 11. 3 %, 10. 0 %, and 8. 3 %, respectively, versus 0. 0 % for placebo (p < / = 0. 05 for all comparisons).